NCT06919926View on ClinicalTrials.gov

Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 17, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2028

Conditions
Hippocampal OveractivityDementia
Interventions
DRUG

AGB101

low-dose levetiracetam, 220 mg, extended release tablet

DRUG

Placebo

placebo capsule

Trial Locations (1)

21287

RECRUITING

Johns Hopkins University School of Medicine, Baltimore

Sponsors

Collaborators (1)

AgeneBio
All Listed Sponsors
collaborator

AgeneBio

INDUSTRY

collaborator

National Institute on Aging (NIA)

NIH

lead

Johns Hopkins University

OTHER

NCT06919926 - Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults | Biotech Hunter | Biotech Hunter